|
1
|
Yin AH, Miraglia S, Zanjani ED,
AlmeidaPorada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck
DW: AC133, a novel marker for human hematopoietic stem and
progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
2
|
Miraglia S, Godfrey W, Yin AH, Atkins K,
Warnke R, Holden JT, Bray RA, Waller EK and Buck DW: A novel
five-transmembrane hematopoietic stem cell antigen: Isolation,
characterization, and molecular cloning. Blood. 90:5013–5021.
1997.PubMed/NCBI
|
|
3
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
4
|
Todaro M, Francipane MG, Medema JP and
Stassi G: Colon cancer stem cells: Promise of targeted therapy.
Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen S, Song X, Chen Z, Li X, Li M, Liu H
and Li J: CD133 expression and the prognosis of colorectal cancer:
A systematic review and meta-analysis. PLoS One. 8:e563802013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Florek M, Haase M, Marzesco AM, Freund D,
Ehninger G, Huttner WB and Corbeil D: Prominin-1/CD133, a neural
and hematopoietic stem cell marker, is expressed in adult human
differentiated cells and certain types of kidney cancer. Cell
Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shmelkov SV, Butler JM, Hooper AT, Hormigo
A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et
al: CD133 expression is not restricted to stem cells, and both
CD133+ and CD133, metastatic colon cancer cells initiate
tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
|
|
11
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Collins A and Bloomston M: Diagnosis and
management of pancreatic cancer. Minerva Gastroenterol Dietol.
55:445–454. 2009.PubMed/NCBI
|
|
13
|
Moriyama T, Ohuchida K, Mizumoto K, Cui L,
Ikenaga N, Sato N and Tanaka M: Enhanced cell migration and
invasion of CD133+ pancreatic cancer cells cocultured
with pancreatic stromal cells. Cancer. 116:3357–3368. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nomura A, Banerjee S, Chugh R, Dudeja V,
Yamamoto M, Vickers SM and Saluja AK: CD133 initiates tumors,
induces epithelial-mesenchymal transition and increases metastasis
in pancreatic cancer. Oncotarget. 6:8313–8322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gendler SJ: MUC1, the renaissance
molecule. J Mammary Gland Biol Neoplasia. 6:339–353. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Costa NR, Paulo P, Caffrey T,
Hollingsworth MA and Santos-Silva F: Impact of MUC1 mucin
downregulation in the phenotypic characteristics of MKN45 gastric
carcinoma cell line. PLoS One. 6:e269702011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jonckheere N and Van Seuningen I: The
membrane-bound mucins: From cell signalling to transcriptional
regulation and expression in epithelial cancers. Biochimie.
92:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roy LD, Sahraei M, Subramani DB, Besmer D,
Nath S, Tinder TL, Bajaj E, Shanmugam K, Lee YY, Hwang SI, et al:
MUC1 enhances invasiveness of pancreatic cancer cells by inducing
epithelial to mesenchymal transition. Oncogene. 30:1449–1459. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carraway KL III, Funes M, Workman HC and
Sweeney C: Contribution of membrane mucins to tumor progression
through modulation of cellular growth signaling pathways. Curr Top
Dev Biol. 78:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bafna S, Kaur S and Batra SK:
Membrane-bound mucins: The mechanistic basis for alterations in the
growth and survival of cancer cells. Oncogene. 29:2893–2904. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Singh AP, Chauhan SC, Bafna S, Johansson
SL, Smith LM, Moniaux N, Lin MF and Batra SK: Aberrant expression
of transmembrane mucins, MUC1 and MUC4, in human prostate
carcinomas. Prostate. 66:421–429. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carson DD: The cytoplasmic tail of MUC1: A
very busy place. Sci Signal. 1:pe352008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamamoto M, Bharti A, Li Y and Kufe D:
Interaction of the DF3/MUC1 breast carcinoma-associated antigen and
beta-catenin in cell adhesion. J Biol Chem. 272:12492–12494. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang L, Chen D, Liu D, Yin L, Kharbanda S
and Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase
3beta-mediated phosphorylation and degradation of beta-catenin.
Cancer Res. 65:10413–10422. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fessler SP, Wotkowicz MT, Mahanta SK and
Bamdad C: MUC1* is a determinant of trastuzumab (Herceptin)
resistance in breast cancer cells. Breast Cancer Res Treat.
118:113–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hikita ST, Kosik KS, Clegg DO and Bamdad
C: MUC1* mediates the growth of human pluripotent stem cells. PLoS
One. 3:e33122008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Curry JM, Thompson KJ, Rao SG, Besmer DM,
Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D,
Iannitti DA, et al: The use of a novel MUC1 antibody to identify
cancer stem cells and circulating MUC1 in mice and patients with
pancreatic cancer. J Surg Oncol. 107:713–722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suvarna SK, Layton C and Bancroft JD: The
hematoxylins and eosinBancroft's Theory and Practice of
Histological Techniques. 7th. Churchill Livingstone; London: pp.
178–179. 2013
|
|
29
|
Moon RT, Kohn AD, De Ferrari GV and Kaykas
A: WNT and beta-catenin signalling: Diseases and therapies. Nat Rev
Genet. 5:691–701. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Metzgar RS, Gaillard MT, Levine SJ, Tuck
FL, Bossen EH and Borowitz MJ: Antigens of human pancreatic
adenocarcinoma cells defined by murine monoclonal antibodies.
Cancer Res. 42:601–608. 1982.PubMed/NCBI
|
|
31
|
Vathipadiekal V, Saxena D, Mok SC,
Hauschka PV, Ozbun L and Birrer MJ: Identification of a potential
ovarian cancer stem cell gene expression profile from advanced
stage papillary serous ovarian cancer. PLoS One. 7:e290792012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS,
An S, Hwang SG, Kang SG, Suh Y, Park MJ and Lee SJ: c-Jun
N-terminal kinase has a pivotal role in the maintenance of
self-renewal and tumorigenicity in glioma stem-like cells.
Oncogene. 31:4655–4666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rohner A, Spilker ME, Lam JL, Pascual B,
Bartkowski D, Li QJ, Yang AH, Stevens G, Xu M, Wells PA, et al:
Effective targeting of Hedgehog signaling in a medulloblastoma
model with PF-5274857, a potent and selective Smoothened antagonist
that penetrates the blood-brain barrier. Mol Cancer Ther. 11:57–65.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Horn G, Gaziel A, Wreschner DH,
Smorodinsky NI and Ehrlich M: ERK and PI3K regulate different
aspects of the epithelial to mesenchymal transition of mammary
tumor cells induced by truncated MUC1. Exp Cell Res. 315:1490–1504.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vos HL, de Vries Y and Hilkens J: The
mouse episialin (Muc1) gene and its promoter: Rapid evolution of
the repetitive domain in the protein. Biochem Biophys Res Commun.
181:121–130. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baldus SE, Mönig SP, Huxel S, Landsberg S,
Hanisch FG, Engelmann K, Schneider PM, Thiele J, Hölscher AH and
Dienes HP: MUC1 and nuclear beta-catenin are coexpressed at the
invasion front of colorectal carcinomas and are both correlated
with tumor prognosis. Clin Cancer Res. 10:2790–2796. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Behrens J, von Kries JP, Kühl M, Bruhn L,
Wedlich D, Grosschedl R and Birchmeier W: Functional interaction of
beta-catenin with the transcription factor LEF-1. Nature.
382:638–642. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang L, Ren J, Chen D, Li Y, Kharbanda S
and Kufe D: MUC1 cytoplasmic domain coactivates Wnt target gene
transcription and confers transformation. Cancer Biol Ther.
2:702–706. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Y and Kufe D: The human DF3/MUC1
carcinoma-associated antigen signals nuclear localization of the
catenin p120(ctn). Biochem Biophys Res Commun. 281:440–443. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ren J, Li Y and Kufe D: Protein kinase C
delta regulates function of the DF3/MUC1 carcinoma antigen in
beta-catenin signaling. J Biol Chem. 277:17616–17622. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schroeder JA, Thompson MC, Gardner MM and
Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor
receptor and correlates with mitogen-activated protein kinase
activation in the mouse mammary gland. J Biol Chem.
276:13057–13064. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wen Y, Caffrey TC, Wheelock MJ, Johnson KR
and Hollingsworth MA: Nuclear association of the cytoplasmic tail
of MUC1 and beta-catenin. J Biol Chem. 278:38029–38039. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yuan Z, Wong S, Borrelli A and Chung MA:
Down-regulation of MUC1 in cancer cells inhibits cell migration by
promoting E-cadherin/catenin complex formation. Biochem Biophys Res
Commun. 362:740–746. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gnemmi V, Bouillez A, Gaudelot K, Hémon B,
Ringot B, Pottier N, Glowacki F, Villers A, Vindrieux D, Cauffiez
C, et al: MUC1 drives epithelial-mesenchymal transition in renal
carcinoma through Wnt/β-catenin pathway and interaction with SNAIL
promoter. Cancer Lett. 346:225–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
